Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
about
Gene, Stem Cell, and Alternative Therapies for SCA 1Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1Structural bases for recognition of Anp32/LANP proteinsProtein-protein interactions as a strategy towards protein-specific drug design: the example of ataxin-1Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factorsThe epigenetic effect of nicotine on dopamine D1 receptor expression in rat prefrontal cortexPartial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesisGcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model.Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein.Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model.Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxiasGlial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapyA Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome.Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxiasInterrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin.The importance of serine 776 in Ataxin-1 partner selection: a FRET analysis.Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent mannerTranscriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17.RNAi prevents and reverses phenotypes induced by mutant human ataxin-1.Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.Mapping the self-association domains of ataxin-1: identification of novel non overlapping motifs.Kaleidoscopic protein-protein interactions in the life and death of ataxin-1: new strategies against protein aggregation.Current understanding on the pathogenesis of polyglutamine diseases.RNA therapy for polyglutamine neurodegenerative diseases.A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients.Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3β-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1).Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease.Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS-MAPK signaling pathway.A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1.Suppression of calbindin-D28k expression exacerbates SCA1 phenotype in a disease mouse model.Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.
P2860
Q26738497-C412C295-21ED-488D-A9B8-4ADE088531F9Q27008548-6D5966CF-D8C4-4D5D-8AB0-6004EA1E1739Q27650321-1BC37AEF-0809-4BDB-A134-BC53B8E4F372Q27680453-ADD1E1BC-C2B5-48A1-954A-210897630387Q28472246-B90FF313-4FA8-427F-8025-ED6CD792B35BQ28568723-3A3C17E6-F925-4589-81DC-4A113ED54498Q28593098-697148AD-B634-4C87-9ABD-0887CB9816F4Q30422849-E2B1B3E0-0DAB-4E3D-91A9-8E563A489D80Q33358963-5E0549B0-4705-491B-86A6-83B5E668F512Q33726336-00D9661D-B1CE-46C4-926C-349AE811EDEAQ34066247-97A5D6B9-8815-4515-BB9F-97E41293F83EQ34955481-2203E7DB-1A45-461E-85D5-1167293123EBQ34981549-9E134085-5E17-4A17-AFFB-E1393595904EQ35126073-05AE42B9-A442-4AB8-8535-189ACC08DA34Q35155993-59882E32-C8CF-495B-B9F3-0EA1FEDCC928Q35670193-DE60B87B-E0FE-4F95-974C-56B5201DBED0Q36319566-DAFFB269-95D9-47B3-8588-DFBA2DC4DF9CQ36444032-704095C3-750F-4B72-942E-F6838DFEAFD7Q36981055-2690F787-E03C-4270-941F-958A7B00936EQ37378119-3C5A03BA-FCEC-4EF3-BA67-C431499E1F71Q37423590-E337F02B-DCF5-4071-B90E-9B09A02ED5E6Q37619548-5659164D-E241-46D4-A846-A071CA7060B1Q37675748-E697DB42-EC14-436A-BA96-E243E20C033CQ37706493-E0920201-1879-44B9-A8D9-C9C98F223119Q37760791-09AD47E0-E4F1-4345-A72D-E74EC8C43423Q37980319-4652DEED-3337-40D5-8354-2A11888E36BBQ38962446-FEBED53C-4528-4781-A533-BFC413F80CD3Q39552099-7629BF6A-D98B-487C-91DA-E670C364A012Q42150837-38EBE33B-14A5-4DA4-8FCC-C5E66E958236Q47168246-FD06F43B-37AC-483C-B7C4-4EE752D4124DQ51030072-E81ACD61-B2C0-42EF-B6EE-3212D366BE6AQ54339710-AA11BF3C-D008-4518-A41C-9F705EA4F07BQ54965657-519FD1BF-A0E0-430F-9981-A0F5D92299B8
P2860
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@en
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@nl
type
label
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@en
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@nl
prefLabel
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@en
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.
@nl
P2093
P356
P1476
Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1
@en
P2093
Abigail Hunt
Janice Holton
Massimo Pandolfo
Rajesh P Menon
Robert Goold
Tamas Revesz
P304
P356
10.1093/HMG/DDM162
P577
2007-06-28T00:00:00Z